Celcuity To Participate in Upcoming Investor Conferences
Key Highlights
- ➤Celcuity CEO Brian Sullivan will present at three November investor conferences.
- ➤REVTORPYK received FDA approval for eligible HR+/HER2- advanced breast cancer patients.
- ➤VIKTORIA-2 Phase 3 trial evaluates gedatolisib in two first-line breast-cancer cohorts.
- ➤CELC-G-201 Phase 1b/2 trial evaluates gedatolisib plus darolutamide in prostate cancer.
Expert Statements
Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity
“will present and be available for one-on-one investor meetings at the following investor conferences”
MINNEAPOLIS, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: * A fireside chat at Guggenheim’s 3rd Annual Healthcare Innovation Conference at 3:00 p.m. EST on Tuesday, November 10, 2026. A live webcast will be available using this weblink. * A fireside chat at the Stifel 2026 Healthcare Conference at 10:40 a.m. EST on Wednesday, November 11, 2026. A live webcast will be available using this weblink.
* A fireside chat at Jefferies Global Healthcare Conference in London at 9:00 am EST / 2:00 p.m. GMT on Wednesday, November 18, 2026. A live webcast will be available using this weblink. Alternatively, the live webcasts will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live events.
Get started
Create a free account to read the full story.